Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.59 USD | +0.08% | +0.12% | +58.65% |
Financials (USD)
Sales 2024 * | 204M | Sales 2025 * | 264M | Capitalization | 2.21B |
---|---|---|---|---|---|
Net income 2024 * | -185M | Net income 2025 * | -156M | EV / Sales 2024 * | 10.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.38 x |
P/E ratio 2024 * |
-12.4
x | P/E ratio 2025 * |
-15.7
x | Employees | 355 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.52% |
Latest transcript on Deciphera Pharmaceuticals, Inc.
1 day | +0.08% | ||
1 week | +0.12% | ||
Current month | +0.20% | ||
1 month | +0.91% | ||
3 months | +54.72% | ||
6 months | +67.36% | ||
Current year | +58.65% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Hoerter
CEO | Chief Executive Officer | 53 | 18-05-16 |
Tucker Kelly
DFI | Director of Finance/CFO | 53 | 15-01-31 |
Kevin Brodbeck
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patricia Allen
BRD | Director/Board Member | 62 | 16-08-31 |
Edward Benz
BRD | Director/Board Member | 78 | 19-06-30 |
Ron Squarer
CHM | Chairman | 57 | 19-12-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.05% | 2 M€ | -.--% | ||
0.04% | 248 M€ | +11.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 25.59 | +0.08% | 1,595,917 |
24-06-07 | 25.57 | +0.08% | 506,790 |
24-06-06 | 25.55 | -0.12% | 1,223,851 |
24-06-05 | 25.58 | +0.04% | 2,012,711 |
24-06-04 | 25.57 | +0.04% | 510,524 |
Delayed Quote Nasdaq, June 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.65% | 2.21B | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.47% | 16.37B | |
+2.23% | 13.58B | |
+27.13% | 11.66B |
- Stock Market
- Equities
- DCPH Stock